Emergence of Ertapenem Resistance in an Escherichia coli Clinical Isolate Producing Extended-Spectrum β-Lactamase AmpC | Zendy

Hélène Guillon | Zendy; Didier Tandé | Zendy; Hedi Mammeri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emergence of Ertapenem Resistance in an Escherichia coli Clinical Isolate Producing Extended-Spectrum β-Lactamase AmpC

Author(s) -

Hélène Guillon,

Didier Tandé,

Hedi Mammeri

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01513-10

Subject(s) - ertapenem , escherichia coli , cephalosporin , microbiology and biotechnology , biology , enterobacteriaceae , chromosome , antibiotic resistance , broad spectrum , antibiotics , genetics , chemistry , gene , combinatorial chemistry

Escherichia coli isolate MEV, responsible for a bloodstream infection, was resistant to penicillins, cephalosporins, and ertapenem. Molecular and biochemical characterization revealed the production of a novel, chromosome-borne, extended-spectrum AmpC (ESAC) β-lactamase with a Ser-282 duplication and increased carbapenemase activity. This study demonstrates for the first time that chromosome-borne ESAC β-lactamases can contribute to the emergence of ertapenem resistance in E. coli clinical isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research